WHAT WE DO
We offer strategic support to companies during the drugs’ full lifecycle: from the regulatory process, including the Therapeutic Positioning Report (TPR) development to P&R submission, negotiation and approval, and Market Access at regional and hospital level. We do so by collaborating with relevant stakeholders, scientific societies and patients associations to ensure a successful Pricing and Market Access for innovative drugs in Spain.
OMAKASE LEADERSHIP TEAM
PUBLICATIONS
NEWS & EVENTS
-
The September 2020 summary of P&R decisions from the Spanish Interministerial Medicinal Products Pricing Committee (CIPM) is now translated and available to download in English.The September 2020 summary of P&R decisions from the Spanish Interministerial Medicinal Products Pricing Committee (CIPM) is now translated and available to download in English.
-
Adding up methodologies like GENESIS and Multi Criteria Decision Analysis (MCDA), a way to explore in the near future to improve drugs evaluation in Spain.Adding up methodologies like GENESIS and Multi Criteria Decision Analysis (MCDA), a way to explore in the near future to improve drugs evaluation in Spain.
-
Yesterday, in the 65th SEFH virtual Congress, a panel of 3 experts from Orphar-SEFH group and Dr. Badia from Omakase Consulting shared their experiences about Horizon Scanning reports talking about how to develop it and use it for anticipating new drugs coming to Spain.Yesterday, in the 65th SEFH virtual Congress, a panel of 3 experts from Orphar-SEFH group and Dr. Badia from Omakase Consulting shared their experiences about Horizon Scanning reports talking about how to develop it and use it for anticipating new drugs coming to Spain.
GET IN TOUCH
CONTACT INFO
BARCELONA & MADRID OFFICES
Telephone: +34 674614704 | +34 931890969
E-mail: administracion@omakaseconsulting.com
APPLY FOR A JOB
Please send your CV to: administracion@omakaseconsulting.com
Follow Us On Social Media!